Results 101 to 110 of about 15,580 (201)

Synthesis and Physicochemical Evaluation of Entecavir-Fatty Acid Conjugates in Reducing Food Effect on Intestinal Absorption

Molecules, 2018
The oral bioavailability of entecavir (EV), an anti-viral agent commonly prescribed to treat hepatitis B infections, is drastically reduced under a post-prandial state. This is primarily due to its low permeability in the gastrointestinal tract.
Hyuck Jun Jung, Myoung Jin Ho, Sungwan Ahn, Young Taek Han, Myung Joo Kang   +4 more
doaj   +1 more source

Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver [PDF]

, 2013
Abnormal liver biochemical tests are present in up to 30% of patients with inflammatory bowel disease (IBD), and therefore become a diagnostic challenge.
Ampuero Herrojo, Javier, Castro Fernández, Manuel, Rojas Feria, María, Romero Gómez, Manuel, Suárez, Emilio   +4 more
core   +1 more source

Prospects for Controlling Hepatitis B Globally

Pathogens
Infection with the hepatitis B virus (HBV) is highly prevalent globally. Over 250 million people suffer from chronic hepatitis B, and more than 800,000 patients die each year due to hepatitis B complications, including liver cancer.
Vicente Soriano, Víctor Moreno-Torres, Ana Treviño, Fernando de Jesús, Octavio Corral, Carmen de Mendoza   +5 more
doaj   +1 more source

Entecavir [PDF]

Reactions Weekly, 2020
  +4 more sources

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? [PDF]

Clinical and Molecular Hepatology, 2020
Byoung Kuk Jang
doaj   +1 more source

Experience of entecavir in renal graft recipients with chronic hepatitis B

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2011
Aim of investigation. To estimate efficacy and safety of entecavir (ETV) in chronic hepatitis B (CHB) at renal graft recipients (RGR).Material and methods.
M. L. Zubkin, Ye. P. Sel'kova, F. K. Kokoyeva, T. A. Semenenko, V. I. Chervinko, A. N. Kolomoyets, E. M. Balakirev, A. V. Frolov, T. P. Nekrasova   +8 more
doaj  

Behavioural changes in relation to risk perception and prevention of avian and human influenza in the general population of Hong Kong, 2006 to 2010 [PDF]

, 2014
Conference Theme: Translating Health Research into Policy and Practice for Health of the PopulationPoster Presentation: abstract no. P84-Ab0047BACKGROUND: The Hong Kong government has introduced a series of progressive measures on importation, farming ...
Cowling, B, Fielding, R, Lam, WWT, Liao, Q   +3 more
core  

Evaluación de la costo-efectividad de entecavir versus lamivudina en pacientes con hepatitis B crónica

Acta Gastroenterológica Latinoamericana, 2008
La infección crónica por el virus de la hepatitis B representa una importante carga de enfermedad en el mundo y en Argentina. Existen nuevas estrategias terapéuticas, entre ellas el entecavir, un análogo nucleósido.
Juan Ignacio Calcagno, Federico Augustovski, Adrián Gadano, Alberto Souto, Yong Yuan   +4 more
doaj  

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

Infection and Drug Resistance, 2018
Lei Yan,1,* Chuanwu Zhu,2,* Jing Li,3,* Liwen Chen,1 Yezhou Ding,1 Zhujun Cao,1 Kehui Liu,1,4 Lanyi Lin,1 Weiliang Tang,1 Qing Xie,1 Yumin Xu,1 Shisan Bao,5 Hui Wang1 1Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University ...
Yan L, Zhu C, Li J, Chen L, Ding Y, Cao Z, Liu K, Lin L, Tang W, Xie Q, Xu Y, Bao S, Wang H   +12 more
doaj  

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand [PDF]

, 2014

core   +1 more source